X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
KRM-II-81 is an orally bioavailable imidazodiazepines that acts as a GABA-A receptor potentiator (GABAkine). It is being developed for the treatment of pain.
Lead Product(s): KRM-II-81
Therapeutic Area: Neurology Product Name: KRM-II-81
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2024
Details:
Under the agreement, ResolutionRx will use and exploit the Licensed IP associated with new dronabinol formulations initially to be developed for the treatment of obstructive sleep apnea.
Lead Product(s): Tetrahydrocannabinol
Therapeutic Area: Sleep Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: ResolutionRx
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 09, 2023
Details:
The collaboration aims to to study the possibility of using CX1739, RespireRx’s lead clinical AMPAkine, for the treatment of a major class of GRIA disorders.
Lead Product(s): Ampakine
Therapeutic Area: Rare Diseases and Disorders Product Name: CX1739
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: University College London
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 05, 2023
Details:
The compounds described in these articles were efficacious as anticonvulsants and the most characterized of these, KRM-II-81, KPP-III-34, displayed robust activity in more advanced anti-seizure models. All compounds were effective without producing sedative effects.
Lead Product(s): KRM-II-81
Therapeutic Area: Neurology Product Name: KRM-II-81
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 03, 2023
Details:
KRM-II-81 analogs enhances the GABAergic neurotransmission and function as orally-bioavailable anti-seizure agents in the absence of the sedation typically associated with GABA augmentation.
Lead Product(s): KRM-II-81
Therapeutic Area: Neurology Product Name: KRM-II-81
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 03, 2023
Details:
D9-THC (dronabinol, D9-tetrahydrocannabinol) is an oral capsule drug product that is being tested for clinical efficacy in patients with obstructive sleep apnea (OSA).
Lead Product(s): Tetrahydrocannabinol
Therapeutic Area: Sleep Product Name: D9-THC
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: University of Illinois
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 23, 2023
Details:
Dronabinol, delta-9-THC, is a synthetic version of the naturally occurring substance in the cannabis plant. Drug is an endocannabinoid CB1 and CB2 receptor agonist which is being developed for the treatment of Obstructive sleep apnea.
Lead Product(s): Tetrahydrocannabinol
Therapeutic Area: Sleep Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 12, 2023
Details:
GABAkine, KRM-II-81, has been shown to be effective in relieving acute, chronic, and neuropathic pain without tolerance development. KRM-II-81 preferentially bound to specific subtypes of GABAA receptors to inhibit pain sensory neurons in the spinal dorsal root ganglia.
Lead Product(s): KRM-II-81
Therapeutic Area: Neurology Product Name: KRM-II-81
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institute for Neurological Disorders and Stroke
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 05, 2022
Details:
RespireRx’s ResolutionRx business unit is developing dronabinol, ∆-9-THC, a synthetic version of the naturally occurring substance in the cannabis plant, for the treatment of OSA.
Lead Product(s): Tetrahydrocannabinol
Therapeutic Area: Sleep Product Name: ResolutionRx
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 08, 2022
Details:
After having shown positive activity in animal models of ADHD, CX717, lead AMPAkines, demonstrated statistically significant improvement of symptoms observed in a Phase 2 human clinical trial in adult patients with ADHD.
Lead Product(s): CX717
Therapeutic Area: Psychiatry/Psychology Product Name: CX717
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
